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being that this “relative” area of stenosis will have a higher
velocity and lead to improved patency. Do the authors have any
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Dr Gregory J. Landry (Portland, Ore). The authors present their
data on inferior vena cava reconstruction during retroperitoneal tumor
resection, an experience of 47 patients over 2 decades. The results are
exemplary, with no perioperative mortality and a complication rate of
only 10%, most of which were transient. This is remarkable given the
extensivenatureof theseprocedures,which typically include severalhours
of surgery by the surgical oncologists in addition to the extensive vascular
reconstruction performed by the consulting vascular surgeon.
The data that Dr Quinones has presented are commendable
and to a certain degree unassailable. These patients have a horrible
problem with few alternatives. When it comes to cancer, typically
you gotta do what you gotta do. Surgical treatment at centers of
excellence such as UCLA is their best and often last hope. Most of
my questions are therefore of a technical and philosophical nature:
1. Do the authors have any information on the functional out-
comes of these patients? Most patients state that they prefer
quality of life over quantity of life. How many patients are able
to return to their preoperative level of function? How many
require placement in skilled nursing facilities? I note in partic-
ular one patient was 89 years old and wonder howmuch benefit
this patient actually received from this procedure.
2. Follow-up data were available on only 30/47, or 64%, of patients.
The lost-to-follow-up group is one with which we struggle in the
vascular literature, yet it is one that is important to try to under-
stand. Was the group that did not follow-up a sicker group with
inferior survival? Alternatively, was this a group that was doing so
well that they did not feel that follow-up was necessary?
3. I found it remarkable that suprarenal and retrohepatic caval cross-
clamping was so well tolerated, with the only intervention neces-
sary being fluid boluses. Do the authors use intraoperative echo-
cardiography to assess volume status, and what is their back-up
strategy if cross-clamping is not tolerated?While shunting was not
necessary in any patient, do the authors have a shunt available at
the time of clamping?
4. The authors recommend autogenous patching when bowel is
resected yet favor a synthetic graft in cases where a portion of
the IVC is replaced. In our own experience with caval recon-
struction, as well as with portal vein reconstruction, we have
typically favored autogenous replacement with femoral vein,
using a panel femoral vein graft if necessary to create an appro-
priate size match. Could the authors comment on the use of
alternate conduits, such as autogenous femoral vein and cryo-
preserved conduit, which is advocated by some?
5. Finally, I was curious how the authors came to the decision to
use a smaller (12-14 mm) graft, with the theoretic advantagedata to indicate that the patency of this would be superior to a
prosthetic graft of equal size to the IVC?
I would like to thank the society for asking me to discuss this
aper as well as Dr Quinones and his associates for forwarding this
aper to me well in advance of the meeting.
Dr William Quinones-Baldrich. I appreciate Dr Landry’s review
f our manuscript. I would like to address the questions in the order
resented:
. We do not have any specific information regarding quality of
life. It would be difficult to collect such data as the timing of the
questioning would have a significant impact on the response.
These patients receive chemo and radiation therapy and, cer-
tainly, inquiring about quality of life during those intervals
would be very different than if they were at a different time in
their recovery. In regard to the 89-year-old patient, he is alive
and well 2 years after the intervention.
. We do have follow-up data on all patients regarding survival.
We do not have follow-up imaging on all patients. I would
suspect that the sicker patients more likely had imaging com-
pared to those that did well. It was often difficult to obtain
imaging follow-up in all in part due to the large region from
where these patients were referred.
. Regarding the tolerance of suprarenal and retrohepatic cava
cross-clamping, it has been our experience that this is well
tolerated provided the patient has adequate volume. We coor-
dinate cross-clamping with the anesthesiologist and so far
shunts have not been necessary. We do not use echocardiogra-
phy routinely during these cases.
. Whereas we would favor portal vein reconstruction with autog-
enous material given its small size, we have found a prosthetic
patch to perform well in vena cava reconstructions. We have
used cryopreserved iliac veins in cases of iliac vein resection, but
this would present a cost concern for vena cava reconstruction
when an alternative is clearly available. We reserve autogenous
reconstruction for cases with potential contamination from
bowel resection. In those instances, we prefer to use internal
jugular vein rather than lower extremity vein to avoid an addi-
tional risk factor for lower extremity edema.
. Regarding the choice of smaller diameter ringed-PTFE grafts for
vena cava replacement, we do not have specific data as to its
superiority over larger-diameter grafts. We do believe that increas-
ing velocity of flow through the replaced segment is a potential
advantage and certainly has worked well in our experience.I want to thank theDr Landry for his excellent questions and the
estern Vascular Society for the opportunity to present our study.
